Empathogen for PTSD; FDA rejected Lykos's application August 2024, additional Phase 3 required.
MDMA is a synthetic phenethylamine first patented by Merck in 1912 and rediscovered as a psychoactive compound in the 1970s by chemist Alexander Shulgin. Pharmacologically it is classified as an entactogen or empathogen: it triggers release of serotonin, dopamine, and norepinephrine, reliably producing elevated mood, increased interpersonal trust, and reduced fear response. Those properties are why MDMA is studied for PTSD — a disorder defined by a chronically over-active fear response that makes exposure-based therapy difficult to tolerate.
MDMA is not a classic serotonergic psychedelic like psilocybin or LSD. It does not primarily act at the 5-HT2A receptor, and it does not produce the perceptual changes (visual imagery, ego dissolution) that those compounds do. It sits in its own category.
In the Phase 3 protocol used by MAPS / Lykos, treatment is three all-day dosing sessions, each 2–4 weeks apart, with one male and one female co-therapist in the room. Each session is 8 hours and is preceded by three preparation sessions and followed by three integration sessions (non-drug therapy). Total protocol: 12–18 therapy contacts over ~12 weeks.
The dose is typically 120–180 mg, with an optional supplemental half-dose ~90 minutes in. The therapy component is roughly "inner-directed": the therapists mostly let the patient lead, stepping in for structured check-ins, music transitions, and somatic work. This model is different from ketamine clinics, where the dosing is brief and the therapy is usually separate.
The FDA’s specific concerns, summarized from the CRL and the June 2024 FDA Psychopharmacologic Drugs Advisory Committee (which voted 9-2 and 10-1 against efficacy and benefit-risk):
In October 2024 Lykos accepted the FDA’s view that the path forward requires a fresh Phase 3 trial and announced an independent third-party review of prior data. As of early 2026 there is no public resubmission date.2
Two published pivotal trials showed large treatment effects:
These effect sizes are among the largest ever reported for a PTSD pharmacotherapy. The FDA’s position is that the effect is real but the trials did not convincingly isolate it from expectancy and unblinding.
None of these have a Phase 3 program.
Serotonin syndrome is a life-threatening risk when MDMA is combined with SSRIs, SNRIs, MAOIs, or tramadol — trial protocols required tapering these medications before dosing. MDMA also has abuse liability (it is Schedule I) and has been associated with hyperthermia-related deaths in unregulated recreational settings.
Long-term neurotoxicity at therapeutic doses remains a subject of debate. Animal studies of very high repeated doses show serotonergic axon loss; clinical-dose trials have not demonstrated persistent cognitive effects, but the Phase 3 trials were not powered to detect subtle changes.
MDMA is Schedule I in the United States: no accepted medical use, and research requires DEA Schedule I registration plus an FDA Investigational New Drug (IND) authorization. The August 2024 CRL did not change that status.
Outside the US, Australia rescheduled MDMA to allow prescription for PTSD in July 2023 under the Therapeutic Goods Administration’s Authorised Prescriber scheme — a limited pathway that still requires individual patient approval. No other country has formally approved MDMA therapy as of 2026.
Clinical trials. The MAPS Public Benefit Corporation and Lykos Therapeutics maintain trial listings; additional MDMA trials run through academic centers. Check ClinicalTrials.gov for current recruitment in the United States.
FDA Expanded Access / "compassionate use." Limited pathway for individual patients where no alternative exists; requires treating physician sponsorship and FDA authorization. Small number of patients treated to date.
Australia (residents only). Authorised-prescriber scheme; cost is high and not covered by Medicare.
What not to do. Self-administering MDMA sourced from unregulated supply carries substantial risks — purity variance (especially adulteration with methamphetamine, cathinones, or nothing at all), dose uncertainty, no therapeutic structure, and no ability to respond to medical emergencies. The Phase 3 outcomes should not be assumed to generalize to unmonitored use.
The MDMA protocol integrates non-drug therapy sessions directly into treatment — this is not optional and is not a separate product. See the integration therapy guide for what good preparation and post-session work looks like across modalities.